WALTHAM, Mass., March 5, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today the closing of its previously announced underwritten public offering of common stock. The total number of shares of common stock sold was 5,428,000, composed of 4,720,000 shares of common stock initially offered and an additional 708,000 shares of common stock sold pursuant to the full exercise of the underwriters' over-allotment option, in each case at a public offering price of $18.00 per share. As a result, aggregate net proceeds to the Company, after underwriting discounts and commissions and other estimated offering expenses, will be approximately $91.2 million.
The Company expects to use the net proceeds of this offering to fund its development programs, including clinical trials for its product candidates, rolapitant, niraparib and TSR-011; and for working capital and general corporate purposes. The Company may also use a portion of the proceeds to in-license or acquire, as the case may be, product candidates, technologies, compounds, other assets or complementary businesses, though the Company has no current understandings, agreements or commitments to do so.
Citigroup and Morgan Stanley acted as joint book-running managers for the offering with Leerink Swann, Deutsche Bank Securities, BMO Capital Markets and Baird acting as co-managers for the offering.
The shares described above were issued by TESARO pursuant to a registration statement on Form S-1 declared effective by the Securities and Exchange Commission (SEC) on February 27, 2013. The offering was made only by means of a prospectus, copies of which may be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone at 1-800-831-9146 or email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties, including, but not limited to, statements regarding the expected use of the net proceeds of this offering. More information about potential factors that could affect TESARO's business and financial results is contained in its annual report on Form 10-K filed with the SEC. The Company does not intend, and undertakes no duty, to update this information to reflect future events or circumstances.
TESARO, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.
The TESARO, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13456
CONTACT: Jennifer M. Davis Senior Director, Corporate Development and Investor Relations +1.781.325.1116 email@example.com